Shuchi Goyal

Shuchi Goyal

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DTDivya Thirumal
Divya Thirumal
RSRakesh K Sindhu
Rakesh K Sindhu
SGShuchi Goyal
Shuchi Goyal
ASAayush Sehgal
Aayush Sehgal
AKAshok Kumar
Ashok Kumar
PKPradeep Kumar
Pradeep Kumar
Psoriasis (PSO) is an inflammatory skin condition that causes a variety of diseases and significantly decreases the life characteristics of patients, and substantially diminishes patients’ quality of life. PSO usually impairs the skin and is linked to various disorders. Inflammation pathology does not only damage psoriatic skin; it shows how PSO impinges other body parts. Many variables interact with one another and can impact the etiology of psoriasis directly or indirectly. PSO has an effect on approximately 2% of the world’s population, and significant progress has been made in comprehending and treating the alternative PSO by novel drug delivery systems. Topical, systemic, biological, biomaterials, and phototherapy are some of the useful therapies for PSO. Nonetheless, topical treatments remain the gold standard for treating moderate PSO. The applicability of several nanocarrier systems, such as lipid nanoparticles, metallic nanoparticles, and certain phytocompounds, has been briefly explored. The present review focuses mainly on traditional therapeutic strategies as well as on breakthroughs in nanoformulations and drug delivery methods for several anti-psoriatic drugs.

20 May 2024 in Nanomedicine
Verified
Journal Article
Closed access
SDSmriti Dhingra
Smriti Dhingra
SGShuchi Goyal
Shuchi Goyal
DTDivya Thirumal
Divya Thirumal
PSPreety Sharma
Preety Sharma
GKGurpreet Kaur
Gurpreet Kaur
NMN. Mittal
N. Mittal
Mesoporous silica nanoparticles (MSNPs) are inorganic nanoparticles that have been comprehensively investigated and are intended to deliver therapeutic agents. MSNPs have revolutionized the therapy for various conditions, especially cancer and infectious diseases. In this article, the viability of MSNPs' administration for lung cancer therapy has been reviewed. However, certain challenges lay ahead in the successful translation such as toxicology, immunology, large-scale production, and regulatory matters have made it extremely difficult to translate such discoveries from the bench to the bedside. This review highlights recent developments, characteristics, mechanism of action and customization for targeted delivery. This review also covers the most recent data that sheds light on MSNPs' extraordinary therapeutic potential in fighting lung cancer as well as future hurdles.

1 November 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
RRRitu Rathi
Ritu Rathi
NMNitin Martandrao Mehetre
Nitin Martandrao Mehetre
SGShuchi Goyal
Shuchi Goyal
ISInderbir Singh
Inderbir Singh
KHKampanart Huanbutta
Kampanart Huanbutta
TSTanikan Sangnim
Tanikan Sangnim
Multidisciplinary research has been conducted on novel drug delivery technologies to maximize therapeutic advantages while curtailing undesirable reactions. Drugs under BCS Class II often have a low bioavailability because the dissolution phase limits the absorption efficiency. In this review, risperidone was used as a pharmacological model to examine the impact of solubility enhancement at the primary administration site for such pharmaceuticals. For tackling drug-related pertains like disease diagnostics, therapy, and prophylactic measures at the cellular or molecular levels, implementing nanocarriers in therapeutics has significant potential. The comprehensive pharmaceutical compositions of risperidone nano-microparticles that have been developed to alleviate psychosis are highlighted in the study, which also illustrates potential future developments in such domains.

13 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SGShuchi Goyal
Shuchi Goyal
MSManjinder Singh
Manjinder Singh
DTDivya Thirumal
Divya Thirumal
PSPratibha Sharma
Pratibha Sharma
SMSomdutt Mujwar
Somdutt Mujwar
SASheikh Fayaz Ahmad
Sheikh Fayaz Ahmad
Alzheimer’s disease (AD) is caused by plaque agglomeration and entanglement in several areas of the neural cells, which leads to apoptosis. The main etiology of AD is senile dementia, which is linked to amyloid-beta (Aβ) deregulation and tau perivascular pathogeny. Hyperphosphorylated tau has a propensity for microtubules, which elevate the instability and tau-protein congregates, leading to accumulation of neurofibrillary tangles (NFTs). Tau hyperphosphorylation is susceptible to GSK-3, which has led to an emerging hypothesis regarding the pathogenesis of AD. Accordingly, attempts have been made to conduct investigations and achieve further advancements on new analogues capable of inhibiting the GSK-3 protein, which are currently in the clinical trials. In this analysis, we have evaluated certain GSK-3 inhibitor variants utilising scaffolding and framework devised techniques with pharmacological characteristics, accompanied by computational screenings (pharmacokinetics and docking). The structure-based designed analogues interacted effectively with the active amino acids of GSK-3β target protein. The in silico pharmacokinetic studies revealed their drug-like properties. The analogues with best interactions and binding scores will be considered in the future to completely demonstrate their potential relevance as viable GSK-3 inhibitors.

6 June 2025 in Journal of Integrated Science and Technology
Verified
Journal Article
Open access
PDF file
AKAjay Kumar
Ajay Kumar
SGShuchi Goyal
Shuchi Goyal
SKSahil Kumar
Sahil Kumar
SSSumitra Singh
Sumitra Singh
RSRakesh K Sindhu
Rakesh K Sindhu
The growth in the field of nanotechnology has brought forth the growth of several breakthroughs that have prompted formulation of new solutions. Nanocarriers occur as minute encapsulating agents of the drug molecules thus stabilizing and improving the therapeutic effects of the encapsulated drugs. The self-assembly characteristic of proniosomes reduces the challenges that are normally encountered in liposomal and niosomal drug delivery systems. Due to their ability to self-assemble, proniosomes are the focus of constant investigating in the field of drug delivery systems. However, there is still great potential for future research concerning the development of new carrier materials for proniosomal formulation. Versatile proniosome-derived niosomes prove to be a reliable and relatively inexpensive system for drug delivery that possesses a number of significant advantages over conventional vesicular and traditional pharmaceutical formulations. Bioactive agents and recent advancements along with ethical considerations in the formation of proniosomes for psoriasis is further discussed in this review article. Novel hypotheses estimate repeated improvements in oral biopharmacokinetics, preferential drug targeting to the site of action, postponing the systemic biotransformation of the drug, which would lead to minimizing toxicity.